MedTrace Logo

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

NCT05182866 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-08-16

No results posted yet for this study

Summary

A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma

Conditions

Interventions

COMBINATION_PRODUCT

ASP-1929 Photoimmunotherapy

ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy

Sponsors & Collaborators

  • Shimadzu Corporation

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • Rakuten Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Vassiliki Saloura, MD · National Cancer Institute (NCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-21
Primary Completion
2024-07-11
Completion
2026-06-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182866 on ClinicalTrials.gov